STERIS plc

STE Healthcare Medical - Devices NYSE

PDF Back to Search

$263.27

+$3.76 (+1.45%)

Open: $260.57 | High: $264.41 | Low: $260.53 | Prev Close: $259.52

Market Cap: $25.93B

Volume: 116K | Avg: 644K

Last updated: January 26, 2026 at 06:05 PM
Featured In

This stock appears in the following dashboards:

Options Activity
Featured
Unusual Options
Featured
Options Screener
Featured
Options Activity for STE
Options Screener Data
Type Strike Expiration Premium Premium Yield Call Vol Put Vol P/C Ratio Rating
N/A $N/A N/A $N/A N/A% N/A N/A N/A N/A/10
View Full Options Screener
Puts/Calls Activity
Type Strike Expiration Premium Volume ROI % Breakeven Delta
N/A $N/A N/A $N/A N/A N/A% $N/A N/A
View Full Options Activity
Investment Rating
B

Neutral

Overall Score: 60/100

Rating Breakdown:
DCF Score 4/5
80%
Buy
ROE Score 3/5
60%
Neutral
ROA Score 4/5
80%
Buy
D/E Score 2/5
40%
Sell
P/E Score 2/5
40%
Sell
P/B Score 2/5
40%
Sell
Add to Watchlist Add to Portfolio
Stock Score Analysis
D

Stock Score: 550

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 25
Financial Health 80
Growth 70
Market Sentiment 10
Risk 50
Lower is better
Valuation 15
Momentum 0
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 37.72
P/B Ratio 3.70
P/S Ratio 4.55
EPS $6.98
Beta 1.03
Shares Outstanding 98.49M
Price Range & Moving Averages
52-Week High $269.44
52-Week Low $204.90
SMA 50 $259.01
SMA 200 $243.16
Dividend Information
Dividend Yield 0.91%
Annual Dividend $2.40
Earnings
Next Earnings February 04, 2026 09:00 PM ET
Financial Ratios
Margins
Gross Margin 44.3%
Operating Margin 17.1%
Net Margin 12.1%
Returns
ROE 10.2%
ROA 6.6%
Liquidity & Leverage
Debt/Equity 0.29
Current Ratio 2.37
Quick Ratio 1.63
Balance Sheet
Total Assets $10.15B
Total Liabilities $3.53B
Total Equity $6.60B
Cash $171.70M
Total Debt $2.20B
Net Debt $2.03B
Income Statement
Revenue $5.46B
Gross Profit $2.40B
Operating Income $866.64M
Net Income $614.64M
EBITDA $1.36B
Revenue/Share $57.95
Cash Flow
Operating CF $1.15B
CapEx $370.09M
Free Cash Flow $778.00M
Book Value/Share $71.37
Tangible Book/Share $10.76
Equity/Share $71.23
Technical Indicators
RSI (14) 50.00 Neutral
MACD
0.00 Signal: 0.00
Volatility 0.00%
Trading Signal Neutral
Performance & Returns

Insufficient historical data

Insufficient historical data (need 200+ days, have 0)
Sector Comparison (Healthcare)
Compared to 45 peers in Healthcare
Metric STE Sector Avg Percentile
P/E Ratio 37.72 35.23 68%
P/B Ratio 3.7 0.19 46%
ROE (%) 10.21% 14.26% 33%
Net Margin (%) 12.07% 9.60% 48%
Stock Score 550 466.0 80%
Percentile: 0% = worst in sector, 100% = best in sector
Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
STE $263.27 $0.00 $0.00 $0.00 $0.00 $0.00 50.00 0.00 0.00% 0 Neutral Mixed
Candlestick Patterns

There wasn't any recognizable pattern for the STE stock

News Sentiment
📊 Ticker 📰 Headline 💭 Sentiment 📡 Source 🔗 URL
STE SG Americas Securities LLC Sells 11,880 Shares of STERIS plc $STE Neutral defenseworld.net Read More
STE STERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results on February 5, 2026 Neutral globenewswire.com Read More
STE METTLER TOLEDO Announces Michael J. Tokich to Join Board of Directors Neutral businesswire.com Read More
STE Fiduciary Family Office LLC Lowers Stock Position in STERIS plc $STE Neutral defenseworld.net Read More
STE 3 Undervalued Medical Instrument Stocks Poised to Grow in 2026 Neutral zacks.com Read More
Recent Insider Trading
Date Insider Position Transaction Shares Price Value
2026-01-01 McGowan Lindsey officer: VP, Chf. Comp. & Quality Offc. SELL 2480 $219.97 $545526
2026-01-01 McGowan Lindsey officer: VP, Chf. Comp. & Quality Offc. SELL 2008 $251.34 $504691
2026-01-01 McGowan Lindsey officer: VP, Chf. Comp. & Quality Offc. SELL 2056 $267.66 $550309
Showing last 10 insider transactions. Green badges indicate purchases (bullish signal), red badges indicate sales.
Company Information

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

CEO Daniel A. Carestio
Employees 18000
Country IE
IPO Date 1992-06-01
Exchange NYSE
Website https://www.steris.com
Sector Healthcare
Industry Medical - Devices
Similar Stocks (Healthcare - Medical - Devices)
ABT

Abbott Laboratories

Price: $108.43
Change: +0.94%
Market Cap: $1887B
P/E: 29.15
Score: E (510)
View Details
BSX

Boston Scientific Corporation

Price: $93.74
Change: +1.33%
Market Cap: $1390B
P/E: 50.13
Score: E (520)
View Details
SYK

Stryker Corporation

Price: $357.20
Change: +0.61%
Market Cap: $1366B
P/E: 47.00
Score: E (520)
View Details
EW

Edwards Lifesciences Corporation

Price: $84.12
Change: +0.56%
Market Cap: $4938B
P/E: 36.89
Score: D (545)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.